HPB P24 Comparison of outcomes of Deb-TACE in patients with HCC larger than 5cm compared with HCC less than 5cm

Abstract Background Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with intermediate-stage hepatocellular carcinoma (HCC). Drug-eluting bead (Deb)-TACE is associated a reduction liver toxicity and drug-related adverse effects compared chemotherapy-TACE. This retrospective paired cohort study compares the outcomes of DEB-TACE HCC greater than less 5 centimeters. Methods Sixty-nine had Deb-TACE as primary treatment for over 3-year period from May 2019 -to 2022. Patients were into two unmatched groups according to tumour size. Group A; size > 5cm group B < 5cm. Each was then following single or repeated Deb-TACE. Tumour response evaluated using standardised modified Response Evaluation Criteria Solid Tumours (mRECIST) detect evidence regression. classified having either complete (CR), partial (PR), stable disease (SD),or progressive (PD). Also, any including hepatic decompensation recorded Results A,(34.48%) 10 session Post-treatment surveillance showed that 4 (44.44%) CR, PR 2 (22.22%), SD 1 patient (11.11%), (22.22%) PD, one still waiting his follow-up surveillance. On other hand,(65.52%)19 sessions, CR evident (10.5%), (5.2%), 3 (15.7%), PD 7 (36.84%) initial followed by (10.5%) finally became PD. B, 18 (45%) Deb-TACE, showing 7(58.3%), detected (16.67%), (8.33%) SD, (16.67%%) 6 their surveillance, no them. (55%) 22 sessions. patients(13.6%) (18.18%), (4.5%) (27.27%). However, (13.6%) CR,3 (9%) CR. Conclusions effective HCCs rate 66.67% who Single dose first it increased 79% deb-TACE; however, not statistically significantly different (P = 0.48). The <5 cm responses up 83% single-dose 59% DEB-TACE, this significant 0.25) . There difference complications between groups.